uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Intranasal Insulin as a Treatment for Alzheimer's Disease: A Review of Basic Research and Clinical Evidence
Show others and affiliations
2013 (English)In: CNS Drugs, ISSN 1172-7047, Vol. 27, no 7, 505-514 p.Article, review/survey (Refereed) Published
Abstract [en]

Research in animals and humans has associated Alzheimer's disease (AD) with decreased cerebrospinal fluid levels of insulin in combination with decreased insulin sensitivity (insulin resistance) in the brain. This phenomenon is accompanied by attenuated receptor expression of insulin and insulin-like growth factor, enhanced serine phosphorylation of insulin receptor substrate-1, and impaired transport of insulin across the blood-brain barrier. Moreover, clinical trials have demonstrated that intranasal insulin improves both memory performance and metabolic integrity of the brain in patients suffering from AD or its prodrome, mild cognitive impairment. These results, in conjunction with the finding that insulin mitigates hippocampal synapse vulnerability to beta amyloid, a peptide thought to be causative in the development of AD, provide a strong rationale for hypothesizing that pharmacological strategies bolstering brain insulin signaling, such as intranasal administration of insulin, could have significant potential in the treatment and prevention of AD. With this view in mind, the review at hand will present molecular mechanisms potentially underlying the memory-enhancing and neuroprotective effects of intranasal insulin. Then, we will discuss the results of intranasal insulin studies that have demonstrated that enhancing brain insulin signaling improves memory and learning processes in both cognitively healthy and impaired humans. Finally, we will provide an overview of neuroimaging studies indicating that disturbances in insulin metabolism-such as insulin resistance in obesity, type 2 diabetes and AD-and altered brain responses to insulin are linked to decreased cerebral volume and especially to hippocampal atrophy.

Place, publisher, year, edition, pages
2013. Vol. 27, no 7, 505-514 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-206395DOI: 10.1007/s40263-013-0076-8ISI: 000321788000002OAI: oai:DiVA.org:uu-206395DiVA: diva2:644534
Available from: 2013-08-30 Created: 2013-08-30 Last updated: 2015-02-23Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Benedict, Christian
By organisation
Department of NeuroscienceFunctional Pharmacology
In the same journal
CNS Drugs
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 157 hits
ReferencesLink to record
Permanent link

Direct link